Alliance Pharma plc (AIM: APH)
London
· Delayed Price · Currency is GBP · Price in GBX42.75
+0.75 (1.79%)
Sep 11, 2024, 5:06 PM GMT+1
Alliance Pharma Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 180.68 | 180.68 | 167.42 | 163.21 | 129.8 | 135.64 | Upgrade
|
| Revenue Growth (YoY) | 7.92% | 7.92% | 2.58% | 25.74% | -4.30% | 14.74% | Upgrade
|
| Cost of Revenue | 75.66 | 75.66 | 65.73 | 53.76 | 46.99 | 49.56 | Upgrade
|
| Gross Profit | 105.02 | 105.02 | 101.68 | 109.45 | 82.82 | 86.08 | Upgrade
|
| Selling, General & Admin | 52.47 | 52.47 | 63.96 | 60.2 | 44.61 | 46.35 | Upgrade
|
| Operating Expenses | 62.46 | 62.46 | 73.25 | 70.98 | 53.14 | 48.35 | Upgrade
|
| Operating Income | 42.56 | 42.56 | 28.43 | 38.47 | 29.67 | 37.73 | Upgrade
|
| Interest Expense | -9.99 | -9.99 | -5.43 | -3.65 | -2.66 | -3.78 | Upgrade
|
| Interest & Investment Income | 0.11 | 0.11 | 0.02 | 0.02 | 0.01 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.48 | -0.48 | 0.06 | 0.21 | -0.65 | -0.8 | Upgrade
|
| EBT Excluding Unusual Items | 32.21 | 32.21 | 23.07 | 35.05 | 26.37 | 33.18 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -2.84 | -1.3 | - | Upgrade
|
| Impairment of Goodwill | - | - | -18.78 | - | -1.14 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.15 | Upgrade
|
| Asset Writedown | -79.25 | -79.25 | -27.71 | -6.15 | -10.91 | -0.28 | Upgrade
|
| Other Unusual Items | -1.75 | -1.75 | 0.37 | -7.9 | - | -1.67 | Upgrade
|
| Pretax Income | -48.8 | -48.8 | -23.05 | 18.16 | 13.02 | 31.08 | Upgrade
|
| Income Tax Expense | -15.66 | -15.66 | -1.84 | 10.84 | 4.99 | 6.07 | Upgrade
|
| Net Income | -33.14 | -33.14 | -21.21 | 7.32 | 8.03 | 25.01 | Upgrade
|
| Net Income to Common | -33.14 | -33.14 | -21.21 | 7.32 | 8.03 | 25.01 | Upgrade
|
| Net Income Growth | - | - | - | -8.82% | -67.90% | 36.25% | Upgrade
|
| Shares Outstanding (Basic) | 540 | 540 | 539 | 535 | 531 | 521 | Upgrade
|
| Shares Outstanding (Diluted) | 540 | 540 | 539 | 542 | 537 | 530 | Upgrade
|
| Shares Change (YoY) | 0.12% | 0.12% | -0.53% | 0.93% | 1.35% | 3.87% | Upgrade
|
| EPS (Basic) | -0.06 | -0.06 | -0.04 | 0.01 | 0.02 | 0.05 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.06 | -0.04 | 0.01 | 0.01 | 0.05 | Upgrade
|
| EPS Growth | - | - | - | -9.40% | -68.43% | 31.11% | Upgrade
|
| Free Cash Flow | 30.71 | 30.71 | 20.61 | 37.13 | 36.96 | 31.61 | Upgrade
|
| Free Cash Flow Per Share | 0.06 | 0.06 | 0.04 | 0.07 | 0.07 | 0.06 | Upgrade
|
| Dividend Per Share | - | - | 0.018 | 0.017 | 0.016 | 0.005 | Upgrade
|
| Dividend Growth | - | - | 5.03% | 5.03% | 200.37% | -63.39% | Upgrade
|
| Gross Margin | 58.12% | 58.12% | 60.74% | 67.06% | 63.80% | 63.46% | Upgrade
|
| Operating Margin | 23.56% | 23.56% | 16.98% | 23.57% | 22.86% | 27.82% | Upgrade
|
| Profit Margin | -18.34% | -18.34% | -12.67% | 4.48% | 6.18% | 18.44% | Upgrade
|
| Free Cash Flow Margin | 17.00% | 17.00% | 12.31% | 22.75% | 28.47% | 23.31% | Upgrade
|
| EBITDA | 50.23 | 50.23 | 36.38 | 46.3 | 37.78 | 38.66 | Upgrade
|
| EBITDA Margin | 27.80% | 27.80% | 21.73% | 28.37% | 29.11% | 28.50% | Upgrade
|
| D&A For EBITDA | 7.66 | 7.66 | 7.95 | 7.83 | 8.11 | 0.93 | Upgrade
|
| EBIT | 42.56 | 42.56 | 28.43 | 38.47 | 29.67 | 37.73 | Upgrade
|
| EBIT Margin | 23.56% | 23.56% | 16.98% | 23.57% | 22.86% | 27.82% | Upgrade
|
| Effective Tax Rate | - | - | - | 59.69% | 38.33% | 19.52% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.